TNFSF13B and systemic lupus erythematosus: Belimumab was the first targeted treatment, approved in 2011, for the treatment of SLE, but its clinical efficacy is limited and not all patients benefit from treatment; this also holds true for other BAFF-blocking agents that have been tested in clinical trials (34).